Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation

Launched by M.D. ANDERSON CANCER CENTER · Aug 10, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how treatment for locally advanced non-small cell lung cancer (a type of lung cancer that has spread to nearby tissues or lymph nodes) affects heart health. The researchers want to understand the risk of heart problems that might arise from a specific treatment called chemoradiation, which combines chemotherapy and radiation therapy. They also aim to see if they can reduce this risk by personalizing the treatment based on each patient’s individual health profile.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of non-small cell lung cancer. You should be able to perform a simple walking test and have good overall health as indicated by a Karnofsky performance status of 70 or higher, which means you can take care of yourself but may need some help. Participants will undergo some tests, including cardiac imaging, to monitor heart health during the treatment. The trial is currently looking for volunteers, and it’s important to note that certain health conditions may prevent someone from joining, such as previous radiation treatment to the chest or being pregnant.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient with histologic diagnosis of non-small cell lung cancer, small cell lung cancer, or limited stage - small cell lung cancer (L-SCLC)
• • 2. The recommended treatment is thoracic radiation therapy combined with concurrent systemic therapy (chemotherapy and/or immunotherapy) with or without neoadjuvant and/or adjuvant systemic therapy (chemotherapy, immunotherapy, targeted therapy)
• • 3. \>/= 18 years of age
• • 4. KPS \>/= 70
• • 5. Willing and able to sign informed consents
• • 6. Willing to perform 6minute walking test
• • 7. Willing to preform required cardiac biomarker test for primary end point assessment.
• Exclusion criteria:
• • 1. Unable or unwilling to give written informed consent
• • 2. Previous history of RT to the thorax overlapping with the current treatment field.
• • 3. Pregnant or breast-feeding
• • 4. Renal failure necessitating dialysis
• • 5. Unwilling to perform protocol tests
• • 6. Contraindication for any protocol tests